Company profile: Polyganics
1.1 - Company Overview
Company description
- Provider of bioresorbable medical devices for natural tissue repair and regeneration, developing, manufacturing, and marketing products including LIQOSEAL dura sealant patch for watertight dural closure; dental and bone grafting materials such as GUIDOR easy-graft, MatrixDerm, MatrixOss Granules, and SynOss Putty; and dural repair solutions like DuraMatrix-Onlay Plus.
Products and services
- DuraMatrix-Onlay Plus: Sponge-like onlay featuring a leak-resistant top layer for dural repair, protecting against cerebrospinal fluid leakage
- LIQOSEAL: Dura sealant patch achieving watertight closure of the dura mater and reducing cerebrospinal fluid leakage
- SynOss Putty: Calcium phosphate-based bone graft material combined with type I collagen, mimicking natural bone structure for bone grafting
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Polyganics
Precision NanoSystems
HQ: Canada
Website
- Description: Provider of tools and processes for developing and manufacturing nanoparticles for medicines and medical research, offering the NanoAssemblr benchtop instrument for nanoparticle prototyping and for developing nanoparticle-based drugs delivering RNA, small-molecule, and protein therapeutics, and Neuro9Kit to study gene function in neurons and glia cells.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Precision NanoSystems company profile →
NanoCellect Biomedical
HQ: United States
Website
- Description: Provider of microfluidic cell analysis and sorting solutions, including WOLF G2 benchtop cell sorter with two lasers and up to nine colors for gentle bulk or single-cell workflows; VERLO image-guided sorter combining flow cytometry with image analysis for complex samples; N1 single-cell dispenser for 96-/384-well plates; CS1 chiller-stirrer for temperature control; and disposable, sterile microfluidic cartridges without cross-contamination.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full NanoCellect Biomedical company profile →
Microbia
HQ: United States
Website
- Description: Provider of industrial biotechnology, developing, producing, and commercializing fermentation-based specialty ingredients and biomaterials, including carotenoids, biopolymers, and other biomaterials; maintains a strategic alliance with Tate & Lyle Investments.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Microbia company profile →
Definigen
HQ: United Kingdom
Website
- Description: Provider of in-vitro liver and metabolic disease models using iPSC technology to generate pre-clinical human data, offering Opti-HEPs for drug efficacy and predictive toxicology screening, phenotypic screening with bioassays, and custom disease model development via CRISPR. Includes models for Alpha-1 Antitrypsin Deficiency, Wilson's Disease (ATP7B), and Glycogen Storage Disease Type 1 Alpha.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Definigen company profile →
CN Bio
HQ: United Kingdom
Website
- Description: Provider of human organ-on-a-chip platforms and services for drug discovery and disease research, including PhysioMimix OOC single- and multi-organ systems, PhysioMimix HT for higher-throughput R&D, contract research services, and liver and lung assays covering NASH, HBV, and COVID-19 for long-term culture, infection modeling, drug efficacy, safety testing, and immune response studies.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full CN Bio company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Polyganics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Polyganics
2.2 - Growth funds investing in similar companies to Polyganics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Polyganics
4.2 - Public trading comparable groups for Polyganics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →